Ocular Therapeutix Inc
NASDAQ:OCUL

Watchlist Manager
Ocular Therapeutix Inc Logo
Ocular Therapeutix Inc
NASDAQ:OCUL
Watchlist
Price: 9.75 USD 7.26%
Market Cap: 1.5B USD
Have any thoughts about
Ocular Therapeutix Inc?
Write Note

Ocular Therapeutix Inc
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ocular Therapeutix Inc
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
Ocular Therapeutix Inc
NASDAQ:OCUL
Other Equity
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Other Equity
-$12.5B
CAGR 3-Years
7%
CAGR 5-Years
4%
CAGR 10-Years
-9%
Bristol-Myers Squibb Co
NYSE:BMY
Other Equity
-$1.5B
CAGR 3-Years
-1%
CAGR 5-Years
0%
CAGR 10-Years
6%
Pfizer Inc
NYSE:PFE
Other Equity
-$7.8B
CAGR 3-Years
-12%
CAGR 5-Years
8%
CAGR 10-Years
-9%
Merck & Co Inc
NYSE:MRK
Other Equity
-$5.4B
CAGR 3-Years
-5%
CAGR 5-Years
0%
CAGR 10-Years
-6%
Eli Lilly and Co
NYSE:LLY
Other Equity
-$4.3B
CAGR 3-Years
12%
CAGR 5-Years
6%
CAGR 10-Years
-5%
No Stocks Found

Ocular Therapeutix Inc
Glance View

Market Cap
1.5B USD
Industry
Pharmaceuticals

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. The company is headquartered in Bedford, Massachusetts and currently employs 228 full-time employees. The company went IPO on 2014-07-25. The Company’s product pipeline candidates provide differentiated drug delivery solutions. The Company’s products include dexamethasone insert (DEXTENZA) and ReSure Sealant. Its DEXTENZA is an intracanalicular insert for the treatment of post-surgical ocular inflammation and pain. Its ReSure Sealant is an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery. The Company’s products that are in pipeline include OTX-TKI for the treatment of wet AMD, OTX-TIC for the treatment of glaucoma and ocular hypertension, OTX-CSI for the chronic treatment of dry eye disease, and OTX-DED for the short-term treatment of the signs and symptoms of dry eye disease.

OCUL Intrinsic Value
2.8 USD
Overvaluation 71%
Intrinsic Value
Price

See Also

Back to Top